Peter Attia's Framework for Deciding Which Supplements and Drugs Are Worth Taking
Attia lays out a rigorous, personalized decision framework for evaluating medications and supplements — cutting through hype with evidence hierarchy and risk math.
Summary
In AMA #85, Peter Attia walks through how to think critically about medications and supplements without defaulting to blanket approvals or rejections. The core principle: define the problem precisely before choosing any intervention. From there, the standard of evidence required should scale with the stakes involved. Attia explains why mechanistic reasoning alone is insufficient, how baseline risk determines real-world benefit, and why relative risk statistics often mislead. He also tackles the practical side — how to run self-experiments, monitor effects without self-deception, and know when to stop a therapy. The episode closes with a frank assessment of the supplement industry's regulatory failures and a short list of over-the-counter supplements Attia considers to have a reasonable evidence-to-risk ratio.
Detailed Summary
Most people approach supplements and medications with a binary mindset — something is either good or bad. Peter Attia argues this framing is fundamentally flawed. The right question is whether a specific intervention makes sense for a specific person with a specific, well-defined problem. Without that starting point, no amount of research review is meaningful.
Attia constructs a tiered evidence hierarchy, arguing that the bar for evidence should match the purpose and stakes of the intervention. A supplement taken for mild cognitive support requires a different evidentiary standard than a medication taken to reduce cardiovascular mortality. Mechanistic plausibility — the idea that something 'should work' based on biology — is a common trap. Attia emphasizes that mechanism rarely translates cleanly to clinical outcome, especially in longevity contexts where endpoint data is nearly impossible to collect.
A central theme is how baseline risk distorts perceived benefit. Relative risk reductions sound impressive but mean little without knowing absolute risk. A 30% relative reduction in an event that affects 1% of people yields a very different real-world benefit than the same reduction in a 20% baseline risk population. Attia argues most people — and many clinicians — fail to internalize this distinction.
The episode also addresses the often-overlooked dimensions of downside: cost, inconvenience, drug interactions, and opportunity cost are just as real as side effects. Attia then offers a practical self-experimentation framework — structuring n-of-1 trials, setting measurable endpoints upfront, and periodically reassessing whether a therapy is still warranted.
Finally, Attia delivers a critical view of the supplement industry, citing poor quality control, contamination risks, and regulatory gaps in the US. He names a small set of OTC supplements he considers to have favorable evidence-to-risk profiles, without specifying all by name in the abstract. The overall message: skepticism is the appropriate default, and clarity of purpose should drive every decision.
Key Findings
- Define the problem precisely first — choosing an intervention before defining the problem is the most common error.
- Evidence standards should scale with intervention stakes; supplements rarely meet the bar required for serious health claims.
- Mechanistic reasoning alone is insufficient to justify taking a supplement or drug, especially in longevity contexts.
- Relative risk reductions are misleading without absolute risk context — baseline risk determines real-world benefit.
- A small subset of OTC supplements may offer a reasonable evidence-to-risk trade-off; most do not.
Methodology
This is a podcast AMA episode, not a peer-reviewed study. Insights are based on Attia's synthesis of published literature, clinical experience, and applied reasoning rather than original data collection. No formal methodology or control group applies.
Study Limitations
This summary is based on the episode abstract and show notes only — the full audio is paywalled. No specific supplements are named in available content, limiting actionability. As a podcast AMA, recommendations reflect one clinician's expert opinion rather than systematic review or guideline consensus.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.